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ABSTRACT
Multiple sclerosis has a long, fascinating, serendipi-
tous, and well-documented history. The first recorded
mention of the disease can be dated back to the fif-
teenth century, while a truly exhaustive investigation
of the disorder began with the nineteenth century’s
burgeoning neurologists. These records reveal a fasci-
nating story of meticulous science aimed at compre-
hending a truly perplexing illness, one that even today
is not completely understood. The great nineteenth
century French neurologist Jean-Marie Charcot became
very interested in studying this disease, and through
his celebrity garnered much attention to a previously
unknown affliction. Here we review a story of pio-
neering research that grants brief tribute to some of
the more remarkable experiments, wondering if ideas
born in the past may help develop solutions in the
future.
A DUTCH SAINT, A BASTARD BRIT, AND THE FATHER
OF NEUROLOGY
For half a millennium of documented effort, medical
professionals have toiled in the attempt to alleviate
their patients of multiple sclerosis. Today this illness
afflicts about 400,000 people in the United States, and
every week another 200 individuals are diagnosed with
multiple sclerosis (MS). Scientific understanding of MS
has evolved from utter bewilderment to an optimistic
investigative insight with novel treatments in the
pipeline. The story of MS is a fascinating journey of
nineteenth and twentieth century medical ingenuity, a
story with its humble scientific beginnings in the
Middle Ages.
The first documented case of MS may be that of Saint
Ludwina of Scheidam of the Netherlands at the turn of
the fifteenth century. Obviously, the differential diag-
nosis of a 500-year-old case is fraught with the limita-
tions of 500-year-old documentation. However, this
particular individual, one eventually canonized as a
saint, has a moderately descriptive biography drawn
from such varied sources as a charter from the Count of
Holland, early accounts of a close relative who lived
with Ludwina for a time, and the copious writings of a
Franciscan priest named Johannes Brugman. It is writ-
ten and confirmed through the use of these multiple
sources that on February 2, 1396, at the age of 16,
Ludwina, a child of previously normal heath, fell and
broke one of her ribs while skating. It was soon real-
ized that her healing was not progressing normally.
Over the course of 37 years, what began early on as dif-
ficulties in walking degraded to partial paralysis as well
as ocular deficits that perhaps can be attributed to
optic neuritis, a common symptom and often a diag-
nostic characteristic of MS (Medaer, 1979). Interestingly,
it seems that remyelination events during the course of
MS illness may explain Ludwina’s periodic remission of
symptoms that at the time were attributed to acts of
God. Thus, it is not a far-fetched idea that MS had a
hand in canonizing a saint.
If one is skeptical towards the belief of Ludwina of
Scheidam as the first documented case of MS, then the
story of Augustus d’Este, an illegitimate grandson of
King George III of England, is probably the first undis-
puted illustration. In his diary, Augustus recorded his
symptoms of MS that began with optic neuritis in 1822
and continued as a 26 year battle with the illness, com-
plete with spontaneous remissions and a progression to
paraperesis (Herndon and Rudick 1989). Clearly, MS has
been with us for a long time.
FIGURE 1 Original drawing by James Dawson from his seminal thesis
on the central nervous system histology of multiple sclerosis.
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Many attribute the emergence of multiple sclerosis
study to the “Father of Neurology,” Jean-Martin
Charcot. However, Charcot himself credited the first
post-mortem description of the disease to Jean
Cruveilhier in an 1838 edition of Atlas d’anatomie
pathologique (Compston, 1999). It is well-documented
that in his efforts to glorify his fellow Frenchmen,
Charcot often overlooked the achievements of other
countries in order to emphasize those of his own. In
fact, the only volume of Cruveilhier’s Atlas illustrating
MS can be confirmed in 1842, four years after the dis-
ease appeared in the work of Englishman Robert
Carswell in his Pathological Anatomy: Illustration of
the Elementary Forms of Disease (Compston, 1999). All
conspiracy theories aside, both physicians were work-
ing in Paris at the time of these gross pathological
descriptions and it is all together likely that they met
and collaborated to some degree. It is perhaps for this
reason, or to avoid a nasty nationalist rivalry entirely,
that both Cruveilhier and Carswell are collectively
given credit for the first clinical description of MS.
Now that MS lesions had been identified in autopsy
specimens, the next challenge was to identify the clini-
cal symptoms in life that would be identifiable with
such pathology. The most important figure in piecing
together an early clinical picture of MS and the indi-
vidual most responsible for garnering worldwide atten-
tion for the disease was Jean-Marie Charcot. Along
with Vulpian, his predecessor as Professor of Pathologic
Anatomy at the Faculty of Medicine in Paris, Charcot
painted a poignant picture of the disease that resulted
from the neurological degeneration illustrated by
Cruveilhier and Carswell. Charcot called this disease
“sclérose en plaques,” a term that first appears in med-
ical literature in 1866 (Dejong 1970).
Another notorious neurological condition was also
being hotly investigated during the nineteenth centu-
ry. Upon the description by James Parkinson of the dis-
ease that was eponymously given his name, there arose
confusion as to how to differentiate Parkinson’s disease
from the “sclérose en plaques” of Charcot. The pro-
nounced shaking tremor found in both diseases was
the basis of this difficulty in establishing a differential
diagnosis. It was through the creative and resourceful
efforts of Charcot that these two neurological syn-
dromes were distinctly classified. In addition to utiliz-
ing a bulky apparatus called a sphygomograph to
demonstrate the differences in frequency and ampli-
tude in the tremors of both diseases, Charcot made the
observation that extremely small handwriting, requir-
ing a magnifying glass to be read, could be used to
characterize Parkinson’s disease (Guillain 1959). Thus,
one of Charcot’s greatest contributions to the under-
standing of MS was discriminating it from Parkinson’s
disease.
The fact that such an eminent scientist of his day
became involved in MS research and consequently
brought great attention to it through the recognition
of his name may interestingly have been an act of
serendipity. It is recorded by two of Charcot’s protégés
that their mentor became particularly interested in the
neurologic disorder after his maid was afflicted by it
(Dejong 1970). Charcot observed the woman’s motor
and sensory functions deteriorate and diagnosed her
with tabes dorsalis, a neurological disorder of the dor-
sal spinal cord commonly associated with syphilis.
However, at the autopsy Charcot observed the sclerotic
plaques that eventually came to characterize MS. By
the turn of the twentieth century MS become one of
the most common neurological admissions, due in no
small part to the influence of Charcot. It is most likely
that the rise in MS admissions resulted from an increase
in clinical awareness rather than a natural epidemic.
MULTIPLE SCLEROSIS AND AN EMERGING FIELD
Though there is a wealth of literary resources available
on the esteemed Charcot, it is equally important to rec-
ognize the contributions of his German contempo-
raries. In 1849, Friedrich von Frerichs first recognized
the pattern of remissions, symptom of nystagmus, and
the effects upon mental state that all were characteris-
tic of MS (Raine, 1997). Contributions of the German
School to nineteenth century neurology also included
the identification of the focal vascular dissemination of
MS lesions by Rindfleisch in 1863 and the identification
of demyelination in MS by Fromman in 1864 (Compston,
1999). At the turn of the century, Otto Marburg put
together a comprehensive clinical picture of acute MS
including the understanding of its myelinotoxic inflam-
matory pathology. At the same time Charcot and the
French school were piecing together the MS neurolog-
FIGURE 2 Another drawing from James Dawson's thesis. Dr. Dawson's
work was the first detailed microscopic investigation of the pathology
of MS using improved nervous tissue staining techniques that emerged
during the early part of the twentieth century.
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ical picture their German counterparts were independ-
ently making key discoveries.
The nineteenth century neurologists made great strides
towards composing a clinical picture of MS as well as
associating the correct post-mortem pathology with
the disease in life; however, little was known about the
underlying cause of MS. Even Charcot admitted that he
did not know what caused the disease, though he did
speculate that MS may have been provoked by an acute
infection, citing associations with cholera, typhoid
fever, and small pox. Pierre Marie, Charcot’s pupil,
became the greatest nineteenth century proponent for
the role of an infectious cause in MS. The idea of an
infectious etiology in the late 1800s may have been
inspired by the recent microbiological revolution
stirred by the work of Louis Pasteur. Interestingly, even
though the definitive cause of MS remains unknown to
this day, the concept of an acute initiator, such as infec-
tious challenge, remains accepted by most specialists in
the field. Perhaps the microbial doctrine originally pro-
posed by nineteenth century neurologists was not as
far off as one might have expected.
At the turn of the twentieth century, the prevailing
theory for the etiology of multiple sclerosis was not the
infectious cause emphasized by Charcot and Marie.
Rather, the scientific community preferred the explana-
tion that MS resulted from an inborn error in myelin
metabolism, and this belief remained dominant until
the conceptualization of autoimmunity early in the
twentieth century. 
The advent of photographic technology revolutionized
the way that medical pathology was recorded, and con-
sequently had a profound impact on the study of MS.
Charcot, a strong proponent for the importance of
medical illustration, was very much involved in the
publication of the third volume Nouvelle Iconographie
in 1890, which most likely included the first photo-
graphs of multiple sclerosis (Compston, 1999). These
photomicrographs presented the spinal cord pathology
of MS in series, and seemed a natural predication for
even greater understanding of the disease’s progres-
sion. One would probably expect that improved diag-
nostic success was destined to follow as the photo-
graphic technology evolved. However, it was not until
the development of magnetic resonance imagery (MRI)
in the late twentieth century that photographic or
radiologic techniques played any routine role in the
diagnosis and treatment of MS.
One of the most interesting issues arising out of nine-
teenth century MS research was the absence of a single
nomenclature. While Charcot and the French used the
term “sclérose en plaques,” the English called the same
disease “disseminated cerebrospinal sclerosis,” and the
German School referenced the term “multiple sklerose”
from nearly the outset. Reports on the subject of MS in
the United States began to emerge during the 1870s,
and an American, Hammond, coined the term “multi-
ple cerebral sclerosis” in 1871. This neurological disease
was also referred to invariably as Charcot’s disease
when Julius Althans named the condition after the
French neurology pioneer in 1877. Curiously, it does
not appear that there was a consistent nomenclature
utilized worldwide until the emergence of patient sup-
port groups in the 1950s.
In addition to the previously established infectious and
inborn error of myelination theories, the turn of the
twentieth century saw other explanations begin to
appear in an attempt to explain the onset of MS. Adolf
Strumpell, in 1896, championed the idea that the
pathology of MS was secondary to glial overgrowth. Yet
others, like Hermann Oppenheim in 1911, looked to a
toxic etiology for an explanation, pointing to tin, car-
bonic oxide, and mercury as potential culprits. Some
investigators simply looked for more definitive data in
the hopes of finally proving one theory over the others.
FIGURE 3 Microscopic drawing of multiple sclerosis by Charcot, demon-
strating the myelin disintegration that is characteristic of the disease.
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In 1917, Kuhn and Steiner thought that they had iden-
tified a specific microbial culprit, a spirochete, that they
believed to be the infectious agent responsible for MS.
NEUROLOGY IN THE TWENTIETH CENTURY
In the early twentieth century, many insightful
advances in the study of MS came from James Dawson
through his work published in the thesis “The Histology
of Disseminated Sclerosis.” Dawson utilized extensive
histological study to construct a sequential model for
MS progression. He noted the process began with
degradation of the myelin sheath, involved glial cell
proliferation, included a fat granule cell formation and
‘fat granule cell myelitis,’ and culminated in progres-
sive sclerosis (Dawson 1916). Dawson’s thorough patho-
logical analysis helped significantly advance the field,
and his comprehensive summary of the current body of
research did much to consolidate and focus the efforts
of other researchers.
A particularly interesting hypothesis came from Richard
Brickner in 1931, with the belief that an abnormal
lipase was to blame for the pathology of MS. Brickner
utilized an acid titration assay to measure differences
in lipid hydrolysis between the contents of serum taken
from MS patients and those not afflicted with the ill-
ness. Though his work did not produce any conclusive
data in support of an abnormal MS lipase, Brickner did
contribute to the understanding of MS disease pro-
gression. He was among the first to assert that even
though the areas surrounding the destruction of
myelin were filled with immune cells, their presence
“was not the result of an inflammatory process to an
infectious agent” (Brickner 1931). Brickner’s abnormal
lipase work illustrates that the twentieth century
brought new efforts to understand the underlying dis-
ease process that could not be simply explained by
infection or congenital myelin malformation.
It is extremely difficult to summarize all of the perti-
nent discoveries of the twentieth century relating to
multiple sclerosis within a short review. For the sake of
brevity, this paper will focus on a few of the more pro-
found and seemingly karmic findings. One of these
experiments of serendipity was conducted by Rivers
and Schwentker in 1935, and may have laid the
groundwork for an autoimmune model of MS. They
demonstrated that injections of normal, sterile rabbit
brain tissue could produce a myelin-destructive
response in monkeys (Rivers and Schwentker, 1935).
Though they still are unwilling to rule out an infectious
etiology in their paper and do not offer an autoim-
mune explanation themselves, Rivers and Schwentker’s
work not only presented some of the earliest data in
support of an autoimmune process but also established
a laboratory standard for studying autoimmunity in the
experimental autoimmune encephalomyelitis model.
Remission of symptoms had been observed in MS per-
haps as early as the case of Saint Ludwina of Scheidam.
However, a mechanism for the cycling of symptoms in
MS had yet to be devised. The work of Mary Bunge,
Richard Bunge, and Hans Ris in 1961 demonstrated for
the first time the process of remyelination, and offered
a convincing new explanation for the spontaneous
remission of symptoms in MS (other theories suggest
spontaneous down-regulation of inflammation within
the CNS). Bunge, Bunge, and Ris introduced lesions into
the subpial spinal cord through repeated injection and
the withdrawal of cerebral spinal fluid. By sixty-four
days after CSF exchange, regions of damaged myelin
were at least thinly remyelinated (Bunge et al., 1961).
Now that remyelination had been firmly demonstrated
and the spontaneous remission of signs could be at
least in part explained neurologically, the scientific
community moved even further along in understand-
ing the pattern and progression of MS.
THE QUESTION OF TREATMENT
For a disease whose underlying cause is as mysterious
as that of MS, it is not surprising that effective treat-
ments have been just as elusive. Charcot, in 1866, held
a pessimistic view of potential treatment:
Need I detain you long over the question
of treatment? The time has not yet come
when such a subject can be seriously con-
sidered. I can only tell you of some experi-
ments which have been tried the results of
which have, unfortunately, not been very
encouraging.
This statement could be used to characterize much of
the treatment attempts up until the 1950’s, when sig-
nificant progress began to manifest. Throughout the
nineteenth century searches for a vaccine, antidotes for
toxins, and chemical therapies such as barium chloride
treatments and carbonic acid baths were all attempted
with little success.
Novel therapies were continually developed in the mid-
1900s, but still less than desirable effects were
achieved. In 1934 an initiative spearheaded by the
American Neurological Association looked to fever
therapy, previously shown to be successful in the allevi-
ation of malaria symptoms, as an answer to multiple
sclerosis. Perhaps focusing on the vascular orientation
of MS pathology, Horton and Wagerer developed his-
tamine-induced vasodilation therapy in 1948 (today it
is understood that such therapy could potentially exac-
erbate the disease by compromising the blood-brain-
barrier even further). Though such novel ideas were
based upon what was believed to be pertinent data,
they still did not offer long-term solutions for disease
treatment.
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Not until the use of corticosteroid therapy to control
the immune process of MS in the 1960s and 1970s was
there a treatment that was at least mildly beneficial.
The effectiveness of immunosuppressive therapy is not
surprising, as it has been shown in recent years that the
invasion of lymphocytes into the CNS via α4-integrin
expression causes influx of myelin-antigen-specific T
cells into the CNS and ultimately destruction of the
myelin sheath. However, it has yet to be established
whether such neurological destruction is the primary
disease process or rather a secondary response. One of
the hopes in unraveling this paradox lies in transcrip-
tional analysis (Steinman and Zamvil, 2001). Using such
analysis, potential therapeutic targets implicated in the
CNS immune invasion, such as IL-23 and osteopontin,
have been identified.
The complexity of MS has made drug design particular-
ly perplexing at times, perhaps best illustrated by the
failure of inhibition therapy of the pro-inflammatory
cytokine tumor necrosis factor-a (TNF-α). While shown
to be profoundly efficacious in rheumatoid arthritis
patients in one trial, anti-TNF-α therapy worsened dis-
ease in MS patients in another trial (LMSSG, 1999). This
paradoxical result perhaps best exemplifies the uncon-
ventional and heterogeneous nature of this disease. It
is likely that a relatively large number of genes con-
tribute to MS quantitatively (Martin et al., 2001), and
one specific gene target or therapy is unlikely to be the
ultimate answer.
Most recently, developments within the field of MS
have become increasingly numerous while the areas of
research have broadened. Some of the most significant
breakthroughs of the late twentieth century in the
realm of MS include: identification of genetic predis-
position at the level of class II MHC, the role of leaki-
ness within the “blood-brain barrier”, the role of
myelin-specific T cell subsets, importance of changes in
adhesion molecules (especially α-4 integrin), evidence
that myelin-specific antibodies are produced early in
the disease course, limits of remyelination, presence of
oligodendrocyte precursors, and the potential of
cytokine therapy. Time will tell which of these areas of
advancement hold the greatest therapeutic value.
CONCLUSION
Today, the science of MS includes theories of molecular
mimicry, talk of superantigens, and clinical trials with
inhibitors of immunologic adhesion molecules. MS
research has certainly come a long way from its humble
nineteenth century beginnings, but some of the same
questions posed by Charcot still exist today. What is the
acute event that underlies the induction of MS? Will we
ever have a truly effective means of treating the neu-
rodegeneration of this disease? Scientists today are still
investigating Charcot’s “sclérose en plaques” at the
laboratory bench and in clinical trials. However, today
in an age of molecular medicine we can beg to differ
with Charcot’s pessimistic nineteenth century outlook
on multiple sclerosis therapy.  Perhaps the time has
finally come to “seriously consider the question of
treatment.”
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